Can the new CEO at Genen­tech main­tain a tra­di­tion of ground­break­ing R&D?

Dur­ing the 6 years that Ian Clark man­aged Genen­tech as its CEO, he nev­er lost sight of the sin­gu­lar mis­sion he had at the big Roche sub­sidiary. Like Pas­cal So­ri­ot be­fore him, and now Bill An­der­son com­ing in af­ter his de­par­ture at the end of this year, job 1 at Genen­tech is keep­ing the phar­ma gi­ant’s unique­ly pro­duc­tive R&D op­er­a­tion fo­cused on big new prod­ucts.

That job pro­file hasn’t changed one bit. This is what Roche’s Daniel O’Day, CEO of Roche’s phar­ma di­vi­sion, had to say on Clark’s re­place­ment at the helm:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN